Anheuser Busch Inbev NV ADR (BUD)vsGilead Sciences Inc (GILD)
BUD
Anheuser Busch Inbev NV ADR
$79.89
-0.45%
CONSUMER DEFENSIVE · Cap: $159.00B
GILD
Gilead Sciences Inc
$131.33
-2.04%
HEALTHCARE · Cap: $166.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Anheuser Busch Inbev NV ADR generates 107% more annual revenue ($60.96B vs $29.44B). GILD leads profitability with a 28.9% profit margin vs 11.9%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).
BUD
Buy63
out of 100
Grade: C+
GILD
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.4%
Fair Value
$70.63
Current Price
$79.89
$9.26 premium
Margin of Safety
+43.2%
Fair Value
$236.08
Current Price
$131.33
$104.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 26.7%
Earnings expanding 20.3% YoY
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 37.4%
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Earnings expanding 23.4% YoY
Areas to Watch
Expensive relative to growth rate
Trading at 10.7x book value
4.7% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : BUD
The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.
Bull Case : GILD
The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Price/Book.
Bear Case : GILD
The primary concerns for GILD are Revenue Growth.
Key Dynamics to Monitor
BUD carries more volatility with a beta of 0.79 — expect wider price swings.
BUD is growing revenue faster at 12.0% — sustainability is the question.
Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GILD scores higher overall (72/100 vs 63/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?